RPG Life Sciences Limited (RPGLIFE.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹2,836.10 (+2.69%) as of
Key statistics
- Market cap
- 46.91B
- P/E (TTM)
- 39.21
- Forward P/E
- 30.11
- EPS (TTM)
- 72.34
- Dividend yield
- 0.87%
- 52-week range
- 1,733.00 – 3,127.80
- Beta
- -0.13
- Revenue (TTM)
- 7.34B
- Profit margin
- 16.29%
- Analyst target
- ₹3,205.00
- Volume
- 10.78k
About RPG Life Sciences Limited
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and domestic and international finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Mumbai, India
- Employees
- 1,366
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.